An observational study in Stem Cell Transplant Complications and Delirium, sponsored by Weill Medical College of Cornell University. Active, not recruiting at 6 sites in 2 countries. Open to participants aged Up to 21 Years. Per ClinicalTrials.gov, last updated 2026-10-23.
Sponsored by Weill Medical College of Cornell University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 263 studies in Delirium with a site in United States — 37 open to participants now, 60 under way, 7 of them phase 3. Delirium · United States.
Among the 263 studies in Delirium with a site in United States, this one is the 5th largest by enrollment of the 69 observational ones that give a count, is one of 13 that started in 2021, is one of 69 observational ones, reaches primary completion later than 21 of the 59 other live ones, and was the 197th registered.
935 studies on the registry are indexed under Delirium; 188 are open to participants now.
Browse Delirium studies →37 of the 263 studies in Delirium with a site in United States are open now. Recruiting first, the newest first:
The Methodist Hospital Research Institute · Sites in United States
Ages up to 65
Northwestern University · Sites in United States
Ages 18+
Ceribell Inc. · Sites in United States
Ages 18+
Washington University School of Medicine · Sites in United States
Ages 60+
Indiana University · Sites in United States
Ages 50+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 124 Delirium studies recruiting now, 96 (77%) set no upper age limit and 8 (6%) stop at 75 or younger; 8 take children under 18; 14 take healthy volunteers.
This study: Up to 21 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
263 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 32 · Phase 3 25 · Phase 4 32
First in 2000; this study’s year is marked. 13 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,040 is above the median of 196 across 343 observational studies indexed under Delirium.
Median enrollment 84 across the 194 interventional studies, 124 across the 69 observational. Of the 171 that completed or were terminated, 68 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 263 have an industry lead sponsor. The 10 most frequent:
Weill Medical College of Cornell University is the lead sponsor of 893 studies on the registry; 165 are open to participants now.
Of its 124 completed or terminated interventional studies of FDA-regulated products, 95 (77%) have results posted.
Weill Medical College of Cornell University has 2 studies filed under Delirium — fewer than ten, so there is no comparison to draw.
22 of the studies in Delirium with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05431595Phase 3M.D. Anderson Cancer CenterManaging Agitated Delirium With Neuroleptics and Anti-Epileptics as a Neuroleptic Sparing Strategy | 2027-02-02 |
| NCT06969287Phase 3Washington University School of MedicineMitigating Delirium With Fluvoxamine Treatment for Non-Cardiac Surgery | 2027-04-01 |
| NCT06192615Phase 3Massachusetts General HospitalMinimizing ICU Neurological Dysfunction With Dexmedetomidine-induced Sleep (MINDDS II) | 2027-10-31 |
| NCT03182335University of ChicagoVasopressor SAT Study | 2026-11 |
| NCT05127265University of FloridaPervasive Sensing and AI in Intelligent ICU | 2026-12 |
Add all 22 to your calendar (.ics) → With an account.
Among the 263 studies in Delirium with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Children undergoing stem cell transplants are at risk for delirium, a temporary change in thinking and behavior. This study will define delirium rates, risk factors, and outcomes. Our eventual goal is to reduce delirium in this population.
Delirium -- defined as an acute change in awareness and cognition that occurs in the setting of an underlying illness -- is a common complication of hematopoietic stem cell transplantation (HSCT) in adults, with associated morbidity and mortality. This has never been studied in children, where risk factors may vary substantially from adults. The objectives of this study are: to define the epidemiology of delirium, and measure its effect on outcomes.
This prospective longitudinal cohort study will prospectively establish the incidence of delirium in 1000 children in the peri-transplant period, and identify modifiable risk factors that predispose to delirium development. This study will also define the effect of delirium on important clinical outcomes, including neurocognitive function. This study will be executed by a research consortium of five leading pediatric oncologic transplant centers in North America, in collaboration with the leading pediatric delirium research group in the United States.
This innovative proposal will leverage the combined experience of the pediatric delirium and HSCT teams to expand urgently needed delirium research into a unique and unstudied population. By reducing delirium rates, outcomes after pediatric HSCT can be optimized.
Subjects will include all patients admitted to the five participating pediatric stem cell transplant sites for the purpose of HSCT during the study period. Enrollment goal is 1000 subjects overall, and 240 subjects for neurocognitive testing. Subjects will be seriously ill. Every patient admitted for HSCT will be eligible for inclusion, unless they are >21 years old. Subjects will be enrolled regardless of gender, race, or ethnicity. No subgroups will be excluded, as delirium likely affects children of all ages and developmental trajectories, with no predilection based on gender, race, or ethnicity.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
A consecutive cohort of children admitted to the hospital for stem cell transplantation
Other: Daily screening for delirium
Each child will be screened twice daily for delirium throughout the transplant hospitalization
Also known as: Cornell Assessment for Pediatric Delirium
Delirium incidence
Number of patients who develop delirium during the course of their transplant hospitalization
Time frame: 1-50 days
Hospital length of stay
Length of transplant hospitalization will be measured in days.
Time frame: 1-365 days
Mortality rate
Count will include number of patients with either in-hospital or post-discharge mortality.
Time frame: 1-5 years
Readmission rate
Count will include number of patients who are readmitted to the hospital within 30-days of discharge.
Time frame: 1-365 days
Change in neurocognitive functioning as measured by the NIH Toolbox Cognition Battery
Neurocognitive functioning will be measured by the NIH Toolbox Cognition Battery, and reported as a total composite score ranging from 50-150. An average score, adjusted for age, is 100. A score lower than 100 indicates lower cognitive functioning than average; a score higher than 100 indicates higher cognitive functioning than average.
Time frame: pre-transplant, 3 months after transplant, 12 months after transplant
Plan to share: Yes — De-identified individual participant data will be shared via NIH-approved repositories within 12 months after publication of primary results. The sharing of unpublished information may be subject to confidentiality issues and will need to be discussed with the appropriate institutions before any request is granted. Access will be granted to qualified researchers with a methodologically sound proposal and appropriate agreements, for academic research, meta-analyses, and other approved studies.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: De-identified IPD will be available no later than 12 months after publication of the primary results and for at least 5 years thereafter.
Access criteria: Access will be granted to qualified researchers with a methodologically sound proposal. Researchers must agree to a data use agreement, and requests will be reviewed by the study team and the Data Coordinating Center.
Ran from Jul 2021 to primary completion in Oct 2026, 62 months.
Of 177 non-industry observational studies under Delirium, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 37. This study's 62 months is above that.
Counting every sponsor, half of 179 studies reached it within 20 months; a quarter within 11 and three quarters within 41.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 23, 2026: primary completion Jul 2026 → Oct 2026 and completion Jul 2026 → Jul 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Weill Medical College of Cornell University →